AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06360445
Drug: Olaparib Tablet reference formulation 100mg
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib Tablet reference formulation 100mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.
Trial: NCT06360445
Drug: Olaparib Tablet test formulation 150mg
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.
Trial: NCT06360445
Drug: Olaparib Tablet reference formulation 150mg
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.
Trial: NCT05431543
Drug: Aceclidine+Brimonidine combination ophthalmic solution
RxNorm normalized name: brimonidine Ophthalmic Solution
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LNZ101-combination ophthalmic solution
Trial: NCT05431543
Drug: Aceclidine ophthalmic solution
RxNorm normalized name: Aceclidine
DrugBank: Aceclidine (DB13262)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNZ100- aceclidine ophthalmic solution
Trial: NCT05431543
Drug: Vehicle proprietary ophthalmic solution
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprietary Vehicle ophthalmic solution
Trial: NCT00246389
Drug: cyclobenzaprine hydrochloride
RxNorm normalized name: Cyclobenzaprine Hydrochloride
DrugBank: Cyclobenzaprine (DB00924)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06454578
Drug: Adebrelimab + Apatinib
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the first 6 months or 8 cycles: Adebrelimab 1200 mg, every 3 weeks； Apatinib 250 mg/day~Maintenance phase： Adebrelimab 1200 mg, every 3 weeks, Maximum maintenance up to 2 years
Trial: NCT04848259
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethason will be given IV before surgery
Trial: NCT04848259
Drug: Honey
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honey will be applied locally after surgery
Trial: NCT04655222
Drug: Interferon Beta Therapy
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT04848259
Drug: Dexamethasone and honey
RxNorm normalized name: Honey
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethason will be given IV before surgery and then Honey will be applied locally after surgery
Trial: NCT04342715
Drug: Sodium stibogluconate / paramomycin
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with Sodium stibogluconate / paramomycin
Trial: NCT06577376
Drug: DP303c
RxNorm normalized name: ADC DP303c
DrugBank: DP-303c (DB17212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DP303c is an antibody conjugate drug (ADC), composed of one anti-HER2 monoclonal antibody coupled to one MMAE via an enzyme specific linker
Trial: NCT06577376
Drug: Irinotecan liposomes
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A chemotherapy
Trial: NCT06577376
Drug: Paclitaxel or docetaxel or irinotecan
RxNorm normalized name: Medicated Pad or Tape
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Paclitaxel or docetaxel or irinotecan is used as a control.
Trial: NCT05389293
Drug: Mosunetuzumab
RxNorm normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During Cycle 1, mosunetuzumab will be administered SC in a step-up dosing schedule at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15). Beginning with Cycle 2, mosunetuzumab will be administered SC at the dose of 45 mg on Day 1. Each Cycle lasts 3 weeks. After the first 8 cycles (approximately 6 months) of therapy, subjects who achieved CR will discontinue therapy, those who attained a PR will receive up to 17 doses (approximately 12 months). Subjects who achieve stable disease (SD) or who experience progressive disease (PD) will be taken off study and subsequent management will be left at the discretion of the investigator.
Trial: NCT05389293
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In Cohort 2, zanubrutinib is concurrently administered continuously starting on Cycle 1, Day -7 and is given for 12 months in both patients with CR and those with PR
Trial: NCT06709521
Drug: Iohexol
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iohexol,N,N´ -Bis(2,3-dihydroxypropyl)-5-\[N-(2,3-dihydroxypropyl)-acetamido\]-2,4,6-triiodoisophthalamide, is a non-ionic, water-soluble radiographic contrast medium with a molecular weight of 821.14 (iodine content 46.36%)
Trial: NCT04889820
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this study, patients with obstructive colon cancer will be divided into two groups; in the control group, curative surgery will be performed within 2 weeks after successful SEMS placement, and in the experimental group, 3 cycles of neoadjuvant chemotherapy will be administered into patients who undergo successful SEMS placement and then curative surgery will be performed after neoadjuvnat chemotherapy. After the surgery, adjuvant chemotherapy will be administered, and total perioperative chemotherapy will be administered with 12 cycles.
Trial: NCT03723057
Drug: AG-221
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral AG-221 administered as directed by treating physician.
Trial: NCT04951713
Drug: XZP-3287 combined with rifampicin
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: XZP-3287, oral, 360 mg once daily for day 1 and day 14 Drug: rifampicin, oral, 600 mg once daily for day 8 to day 19
Trial: NCT05301361
Drug: Methylphenidate Oral Solution
RxNorm normalized name: methylphenidate Oral Solution
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The XRMPH or matching placebo will be started at a dose of 0.3 mg/kg/day and individually titrated over two weeks. Phone calls at the end of weeks 1, 2, and 3 will be used to collect adverse event and response data. If there is no evidence of side effects and ongoing symptoms of ADHD, the dose will be increased to 0.5 mg/kg/day at one week and 0.7 mg/kg/day at 2 weeks (maximum dose of 60 mg per day consistent with FDA labeled use in youth).
Trial: NCT06155487
Drug: AJH-2947 100 mg (SAD)
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablet, Single dose of AJH-2947 100 mg
Trial: NCT06155487
Drug: AJH-2947 200 mg (SAD)
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablet, Single dose of AJH-2947 200 mg
Trial: NCT06155487
Drug: AJH-2947 300 mg (SAD)
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablet, Single dose of AJH-2947 300 mg
Trial: NCT06155487
Drug: AJH-2947 400 mg (SAD)
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablet, Single dose of AJH-2947 400 mg
Trial: NCT06155487
Drug: AJH-2947 600 mg (SAD)
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablet, Single dose of AJH-2947 600 mg
Trial: NCT06155487
Drug: AJH-2947 800 mg (SAD)
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablet, Single dose of AJH-2947 800 mg
Trial: NCT04565392
Drug: Famotidine 20 milligram tablet
RxNorm normalized name: famotidine 20 MG
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet every 12 hours and increase to 1 tablet every 8 hours if not improved by the second day of treatment
Trial: NCT05312021
Drug: IMR-687
RxNorm normalized name: IMRCs
DrugBank: Human Embryonic Stem Cell-derived M Cell (DB15734)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg and 200 mg tablets
Trial: NCT05685719
Drug: STI-1558
RxNorm normalized name: STI-1499
DrugBank: STI-1499 (DB16487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
Trial: NCT05685719
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A strong CYP3A4 inhibitor
Trial: NCT05685719
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A strong CYP3A4 inducer
Trial: NCT06559072
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On the basis of routine treatment for aneurysmal subarachnoid hemorrhage, atorvastatin was administered at an ultra early stage at a dose of 40mg/d for 14 consecutive days
Trial: NCT05932849
Drug: Benralizumab
RxNorm normalized name: Benralizumab
DrugBank: Benralizumab (DB12023)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients were initiated on benralizumab as part of routine clinical practice
Trial: NCT04836507
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to package insert
Trial: NCT05779254
Drug: Neomycin Sulfate
RxNorm normalized name: Neomycin Sulfate
DrugBank: Neomycin (DB00994)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative day-1 Oral Antibiotic Prophylaxis + patients get po. 3x1000mg Neomycin sulfate and 3x500 mg Metronidazole
Trial: NCT05135845
Drug: Capmatinib
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capmatinib 400mg BID for a maximum of 12 months or until progression, patient's refusal or unacceptable toxicity
Trial: NCT05135845
Drug: Spartalizumab
RxNorm normalized name: Spartalizumab
DrugBank: Spartalizumab (DB14892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spartalizumab 300mg Q3W for a maximum of 12 months or until progression, patient's refusal or unacceptable toxicity
Trial: NCT04184609
Drug: Albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mcg of Albuterol will be administered before exercise
Trial: NCT05947851
Drug: Nemtabrutinib
RxNorm normalized name: Nemtabrutinib
DrugBank: Nemtabrutinib (DB18866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 and 20 mg tablets
Trial: NCT05947851
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10, 50, and 100 mg tablets
Trial: NCT06548490
Drug: Semaglutide Pen Injector
RxNorm normalized name: semaglutide Pen Injector
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide will be provided using an injection pen
Trial: NCT06049758
Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution
RxNorm normalized name: enoxaparin 40 mg/0.4 mL injectable solution
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin sodium 40 mg subcutaneous injection will be administered 12 hours before the operation
Trial: NCT06049758
Drug: Levofloxacin 500mg
RxNorm normalized name: LEVOFLOXACIN 500MG TAB
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg intravenous injection will be administered 1 hour before the operation.
Trial: NCT00002401
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002401
Drug: Delavirdine mesylate
RxNorm normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002401
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00002401
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01418599
Drug: Torrent's Alfuzosin Extended Release Tablet
DrugBank: Alfuzosin (DB00346)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05863871
Drug: Linperlisib
RxNorm normalized name: Linperlisib
DrugBank: Linperlisib (DB17235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg, qd
Trial: NCT05717764
Drug: Mitoxantrone hydrochloride liposome injection
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitoxantrone hydrochloride liposome injection will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
Trial: NCT05302024
Drug: Iguratimod
RxNorm normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.
Trial: NCT05230615
Drug: Oral semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Trial: NCT05759000
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sodium-glucose cotransporter-2 (SGLT2) inhibitor is considered one of the four foundational therapies (ACE-I or ARNI, beta-blockers, MRA, and SGLT2 inhibitors) for HFrEF (6). However, guidelines do not specify the sequence and the timing of which therapy to be commenced. In particular, dapagliflozin has been shown in randomized controlled trials to reduce the combined risk of cardiovascular death or HF hospitalization and improve quality of life in HF patients with both reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), respectively, regardless of the presence or absence of diabetes in the DAPA-HF and DELIVER trials (
Trial: NCT06379451
Drug: NKG2D Chimeric Antigen Receptor NK Cell Injection
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administer KN1102 cell injection three times on day 0, day 7, and day 14, respectively.
Trial: NCT05319756
Drug: gabapentin 600 mg
RxNorm normalized name: gabapentin 600 MG
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of gabapentin 600 mg and a placebo that looks like oxycodone HCl
Trial: NCT05319756
Drug: gabapentin 1200 mg
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of gabapentin 1200 mg and a placebo that looks like oxycodone HCl
Trial: NCT05319756
Drug: gabapentin 600 mg and oxycodone HCl 20 mg
RxNorm normalized name: gabapentin 600 MG
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive a single oral dose of gabapentin 600 mg and oxycodone HCl 20 mg
Trial: NCT05319756
Drug: gabapentin 1200 mg and oxycodone HCl 20 mg
RxNorm normalized name: oxycodone and ibuprofen
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive a single oral dose of gabapentin 1200 mg and oxycodone HCl 20 mg
Trial: NCT05319756
Drug: oxycodone HCl 20 mg
RxNorm normalized name: oxyCODONE HCl 20 MG Oral Tablet
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive a single oral dose of oxycodone HCl 20 mg and a placebo that looks like gabapentin
Trial: NCT03636958
Drug: Perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel is an antiepileptic with a novel mechanism of action as it targets post-synaptic AMPA receptors. It has been shown to be effective as adjunctive therapy (dual therapy) for partial / focal epilepsy seizures and generalized in patients over 12 years of age.
Trial: NCT04375813
Drug: eRapa
RxNorm normalized name: Verapamil
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg eRapa (encapsulated rapamycin) oral capsules
Trial: NCT00378456
Drug: Folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05265247
Drug: Esomeprazole 20 mg Delayed-Release Capsules
RxNorm normalized name: esomeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg delayed-release capsules will be given as one capsule once daily as oral administration.
Trial: NCT05265247
Drug: Esomeprazole 20 mg Delayed-Release Capsules (Nexium 24HR)
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg delayed-release capsules (Nexium 24HR) will be given as one capsule once daily as oral administration.
Trial: NCT00852345
Drug: clofazamine
RxNorm normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clofazamine 50mg po qday (duration varies according to physician)
Trial: NCT05440578
Drug: olaparib plus bevacizumab maintenance therapy
RxNorm normalized name: Olaparib
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: First-line olaparib plus bevacizumab maintenance therapy initiated from Aug 2018 up to Dec 2020 (the time range could be extended in order to recruit enough eligible subjects as required).
Trial: NCT04879823
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Dexamethasone Sodium Phosphate will be prescribed orally at a dose of 0.5mg/kg with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The Dexamethasone will be mixed by the parents with 5mL of pre-packaged cherry syrup
Trial: NCT03819296
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT05057767
Drug: Midazolam injection
RxNorm normalized name: midazolam Injection
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: No premedication will be given to Patients in the group undergoing a standardized anesthesia protocol which include induction with thiopental (5 mg/kg) and fentanyl (1-2 μg/kg). Atracurium will be used as a muscle relaxant. After tracheal intubation, anesthesia will be maintained with isoflurane in a concentration of 0.8%-1.2%. Ventilation will be adjusted to produce normocapnia. At the end of surgery, reversal of residual neuromuscular blockade will be accomplished using i.v. atropine 20 μg/Kg and neostigmine 40 μg/kg.
Trial: NCT05813249
Drug: Tocopherol and/or Actos
DrugBank: Tocopherol (DB11251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin E and/or Pioglitazone
Trial: NCT06533852
Drug: Fecal Microbiome Transplantation (FMT)
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses:~First dose: 24 capsules of FMT at baseline. Second dose: 24 capsules of FMT at 3 months.
Trial: NCT06730581
Drug: Utidelone Capsule 60mg/m2/d
DrugBank: Utidelone (DB17575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
Trial: NCT06730581
Drug: Utidelone capsule 75mg/m2
DrugBank: Utidelone (DB17575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
Trial: NCT06730581
Drug: Utidelone Capsule
RxNorm normalized name: Utidelone
DrugBank: Utidelone (DB17575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing regimens were determined based on the results of gastric and ovarian cancer dosing regimens.D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
Trial: NCT06075810
Drug: MBQ-167
RxNorm normalized name: dotatate
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBQ-167, an inhibitor of Rho GTPases Rac and Cdc42
Trial: NCT05045638
Drug: Sotorasib
RxNorm normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral dose